Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenuePayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Drugs Made In America Acquisition (DMAA) Accumulated Expenses (2024 - 2025)

Drugs Made In America Acquisition filings provide 2 years of Accumulated Expenses readings, the most recent being $153988.0 for Q4 2025.

  • Quarterly Accumulated Expenses rose 174.66% to $153988.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $153988.0 through Dec 2025, up 174.66% year-over-year, with the annual reading at $153988.0 for FY2025, 174.66% up from the prior year.
  • Accumulated Expenses hit $153988.0 in Q4 2025 for Drugs Made In America Acquisition, roughly flat from $153988.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $153988.0 in Q1 2025 and bottomed at $56065.0 in Q4 2024.